Alexandria Real Estate Equities (ARE) Stock Analysis
Recovery setup
Real Estate · REIT - Office
Sell if holding. Analyst target reached at $46.68 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Property Type: life science laboratory / Megacampus.
Alexandria Real Estate Equities is a life science REIT with 35.9M RSF of operating properties in innovation clusters including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. It leases lab and Megacampus space to... Read more
Sell if holding. Analyst target reached at $46.68 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Property Type: life science laboratory / Megacampus. Chart setup: Death cross but MACD improving, RSI 73. Score 4.0/10, high confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 62d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Alexandria Real Estate Equities
Latest news
- Alexandria Real Estate Equities Inc. stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
- Unveiling Alexandria Real Estate Equities (ARE) Q1 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance — Yahoo Finance neutral
- Insider Sell: Hallie Kuhn Sells Shares of Alexandria Real Estate Equities Inc (ARE) - GuruFocus — GuruFocus negative
- Hallie Kuhn Sells 536 Shares of Alexandria Real Estate Equities (NYSE:ARE) Stock - MarketBeat — MarketBeat neutral
- Alexandria real estate EVP Hallie Kuhn sells $25,835 in stock - Investing.com — Investing.com negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHPropertylife science laboratory / Megacampus10-K Item 1: 'Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Revenue shrinking — -11.5% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $46.68 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Property Type: life science laboratory / Megacampus. Chart setup: Death cross but MACD improving, RSI 73. Prior stop was $43.41. Score 4.0/10, high confidence.
Take-profit target: $48.02 (+2.9% upside). Prior stop was $43.41. Stop-loss: $43.41.
Concentration risk — Property Type: life science laboratory / Megacampus; Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
Alexandria Real Estate Equities trades at a P/E of N/A (forward -53.0). TrendMatrix value score: 5.3/10. Verdict: Sell.
22 analysts cover ARE with a consensus score of 3.3/5. Average price target: $53.
What does Alexandria Real Estate Equities do?Alexandria Real Estate Equities is a life science REIT with 35.9M RSF of operating properties in innovation clusters...
Alexandria Real Estate Equities is a life science REIT with 35.9M RSF of operating properties in innovation clusters including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. It leases lab and Megacampus space to pharma, biotech, and medical device tenants under long-term triple-net leases with built-in annual rent escalations; 90.9% occupancy as of December 31, 2025.